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Abstract 
Controlled release systems for therapeutic molecules are vital to allow the sustained 
local delivery of their activities which direct cell behaviour and enable novel 
regenerative strategies. Direct programming of cells using exogenously delivered 
transcription factors can by-pass growth factor signalling but there is still a 
requirement to deliver such activity spatio-temporally. We previously developed a 
technology termed GAG-binding enhanced transduction (GET) to efficiently deliver a 
variety of cargoes intracellularly, using GAG-binding domains which promote cell 
targeting, and cell penetrating peptides (CPPs) which allow cell entry. Herein we 
demonstrate that GET system can be used in controlled release systems to mediate 
sustained intracellular transduction over one week. We assessed the stability and 
activity of GET peptides in poly(DL-lactic acid-co-glycolic acid) (PLGA) microparticles 
(MPs) prepared using S/O/W double emulsion method. Efficient encapsulation 
(~65%) and tailored protein release profiles could be achieved, however intracellular 
transduction was significantly inhibited post-release. To retain GET peptide activity 
we optimised a strategy of co-encapsulation of L-Histidine, which may form a 
complex with the PLGA degradation products under acidic conditions. Simulations of 
the polymer microclimate showed that hydrolytic acidic PLGA degradation products 
directly inhibited GET peptide transduction activity, and use of L-Histidine 
significantly enhanced released protein delivery. The ability to control the intracellular 
transduction of functional proteins into cells will facilitate new localised delivery 
methods and allow approaches to direct cellular behaviour for many regenerative 
medicine applications. 
Keywords: Intracellular transduction; Controlled release; GAG-binding enhanced 
transduction (GET), CPP, PLGA, L-Histidine. 
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1. Introduction 
Successful regenerative medicine strategies often rely on exquisite control of the 
biological microenvironment and supplementation of extrinsic therapeutic molecules 
to direct cellular behaviour. Cellular processes like migration, proliferation, adhesion 
and differentiation occur in response to chemical cues present within the 
microenvironment such as interaction with extracellular matrix (ECM) and stimulation 
with morphogens or growth factors [1, 2].  These macromolecules trigger intracellular 
signal transduction pathways, with complex cross-talk between the cascades and 
eventual programming of cell behaviour through transcription factors [2-4]. Our 
recent work has shown that recombinant transcription factors can be expressed, 
purified and delivered efficiently to control cell behaviour for regenerative medicine 
strategies [5]. Such systems will allow the biological control of cells and promote 
regeneration of tissues if it is supplied at a functional dose, duration and location to 
be effective. 
Various methodologies have been developed to deliver therapeutic proteins 
intracellularly [6-8] with the aim to direct differentiation of somatic [9, 10] or stem 
cells [11]; effectively bypassing the need for growth-factor stimulation. Cell 
penetrating peptides (CPPs) can be tethered to the protein of interest [12-14] and 
these trigger endocytosis-mediated uptake when they interact with the cell 
membrane [6-8]. Even though CPPs significantly increase cellular uptake, their 
activity requires them to be in vast extracellular excess to drive endocytosis, with the 
quantities required to elicit changes in cell behaviour at micromolar scale. To 
overcome this inefficiency, we recently described a new technology named 
glycosaminoglycan (GAG) enhanced transduction (GET) [5]. GET technology is a 
series of novel fusion proteins that couple a membrane-docking peptide to heparan 
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sulfate glycosaminoglycans (GAGs) with a PTD. We demonstrated enhanced 
intracellular transduction upon coupling CPPs with a GAG-binding peptide (the 
composite peptide termed GET peptides). Functional quantities of many cargos 
including fluorescent proteins, transcription factors and enzymes were successfully 
delivered using GET peptides with significant increase in functional delivery 
compared to conventional CPP-mediated delivery and using sub-micromolar doses. 
Furthermore we could create 3D gradients of these proteins which mediate cell 
programming dose-dependently [15]. 
In vivo, therapeutic proteins can be delivered by subcutaneous and intramuscular 
administration, or intravenous infusion. However, most proteins possess short 
biological half-lives in bodily fluids which means that frequent injection regimens at 
high dosages are required for sustained effect. Moreover, systemic delivery by 
nature does not allow targeted or localised delivery of proteins, meaning off-target 
effects and significant amounts of the administered therapy is miss-targeted. In order 
to overcome these limitations, biodegradable polymers have been used to control 
the release of therapeutic proteins locally at the disease site. These controlled 
release approaches can be powerful as they extend the duration of activity, 
overcoming the need for frequent administration, and also implantation at the 
therapeutic site allows localized delivery to the tissue of interest [16-19].  
Many studies have employed biodegradable polymer microparticles (MPs), such as 
poly-e-caprolactone, polylactide (PLA), polyglycolide (PGA) and their co-polymer 
poly-lactic and -glycolic acid (PLGA), to mediate controlled release [20-24]. These 
MPs protect the therapeutic cargo from degradation and themselves progressively 
degrade to release the cargo spatio-temporally. PLGA has been extensively studied 
to encapsulate proteins and has been used in long-term delivery systems, with 
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injectable MPs formulations being used to deliver growth factor to promote 
osteogenic differentiation for bone repair. Importantly these proteins have been 
successfully delivered over a period of one month using PLGA MPs [25, 26]. 
However, very few proteins can be easily delivered with this release approach [27], 
as they can undergo physical or chemical degradation during MPs manufacturing of 
these formulations [28-34]. Accordingly, delivery formulations have to be designed to 
protect protein activity during encapsulation and release. Furthermore, MPs loading 
needs to be efficient as delivered formulations have to provide functional quantities 
of protein at the site of injection. 
During MPs fabrication, many factors can affect protein stability, such as protein 
instability at the water – organic interface using double emulsion methods such as 
water-in-oil-in-water (W/O/W) [30], protein–polymer interaction [35], and local acidity 
created within degrading polymer matrix [36-38].  
Several approaches have been developed to protect protein activity during MPs 
fabrication, such as adding excipients to the inner aqueous phase or removing the 
need for the aqueous phase entirely [29, 39-41]. Excipients (such as Cyclodextrin 
and PEG [19, 29, 40, 41]) can be added to compete with the therapeutic protein for 
exposure at the water-organic interface. A study by Morita et al [42] suspended dry 
protein particles in the organic solvent with the aid of PEG, which entirely removes 
the water–organic interface, and is termed solid-in-oil-in-water (S/O/W) double 
emulsion. 
In order to overcome local acidity limitation, many groups studied pH neutralization in 
the PLGA microenvironment [19, 43-45]. Various low soluble basic salts were 
studied, such as magnesium hydroxide [45] and Poly-L-Histidine coupled with PEG 
[19]. The use of these excipients resulted in neutralized acidic microenvironment 
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within the PLGA MPs system. Other issues can arise if the therapeutic proteins 
interacts with the polymer used [19]. Protein–polymer interactions can occur through 
hydrogen bonding, and through hydrophobic or electrostatic interactions [19]. 
Furthermore, proteins may interact with the degradation products of the polymer; 
PLGA degrades through an acid-catalysed hydrolysis and produces carboxylic acid 
molecules which can interact with cationic molecules. Electrostatic and hydrophobic 
interactions are also common factors for protein–polymer complexation [46-48].  
In this study, we demonstrate efficient encapsulation, and release of a GET-tagged 
reporter protein from PLGA MPs. Using a S/O/W double emulsion method we were 
able to fabricate MPs and eliminate the water–organic interface which significantly 
effects protein stability and also removes the need for harsh homogenisation during 
manufacture. PEG was used to pre-form protein nanoparticles, which enabled 
organic solvent resuspension and reduced non-specific protein polymer interaction. 
By using a fluorescently labelled GET-peptide (red fluorescent protein; mR), we were 
able to directly assess the stability and activity of the GET peptides post-release. We 
observed that PLGA degradation resulted in accumulation of acidic products in the 
microenvironment, which can interact with the positively charged GET peptides. 
Therefore we employed L-Histidine as a proton-scavenger to enhance protein 
stability during release. L-Histidine is a positively charged amino acid at pH ≤6, and 
our data suggests it can compete with the GET protein to complex with carboxylic 
acid PLGA degradation products and help retain GET-mediated transduction activity.  
Our optimized controlled release system maintains GET-protein transduction activity 
post-release and allows sustained release of transduction-active GET protein for 7 
days. This approach will allow the localized and sustained delivery of GET-tagged 
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therapeutic molecules and create the potential to target intracellular transduction by 
MPs-mediated controlled release.  
 
2. Materials and methods 
2.1. GET protein and fabrication of MPs 
CPP (eight arginine, 8R) and heparin binding domain; HBD (P21), which compose 
the Glycosaminoglycan – binding enhanced transduction (GET) system were tagged 
with red fluorescent protein (mRFP1) producing P21mR8R protein. GET-mR was 
expressed and purified from Escherichia coli using GST affinity purification as 
previously described [5]. 
Poly (D,L-lactide-co-glycolide, (PLGA) LA:GA ratio: 50:50; Mw 52kDa, Evonik 
Industries, USA) MPs were formed using solid-in-oil-in-water (S/O/W) emulsion as 
previously described by Morita et al. [42], with some modifications. Briefly, 1mg of 
P21mR8R, was mixed with 0.5mg PEG 6000 (Sigma-Aldrich, UK) and freeze dried 
overnight.  For MPs containing L-Histidine, 0.25mg L-Histidine (Sigma-Aldrich, UK) 
was mixed with the P21mR8R–PEG solution and then freeze dried. Blank MPs were 
prepared by freeze drying 0.5mg PEG 6000 only. 15% (w/v) PLGA in 
dichloromethane (DCM, Fisher, UK) (200mg of PLGA was dissolved in 1.5 ml DCM) 
was added to the freeze dried powder, until completely dissolved. The solution was 
then mixed by vortexing. For MPs prepared with phosphate buffered saline (PBS), 
200µL PBS (Gibco, UK) was added to the solution and vortexed to produce 
homogenous emulsion. 4ml of 0.25% (w/v) methylcellulose (Sigma-Aldrich, UK) 
solution was then added to the mixture and vortexed again. The resultant emulsion 
was then poured into 400 ml of distilled water; and the resultant (S/O/W) emulsion 
was left stirring for 3 hours to allow DCM evaporation. The hardened MPs were then 
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collected by centrifugation and washed three times by distilled water (DW). The 
obtained MPs were then freeze dried for 24 hours. 
2.2 MP characterization: Size, charge and morphology  
A thin layer of MPs were placed onto an adhesive stub and gold-coated using a 
SCD030 gold sputter coater (Balzers Union Ltd., Lichtenstein), for five minutes at 30 
mA. The morphology of the MPs was assessed by scanning electron microscopy 
(SEM), using a JEOL 6060L imaging system (JEOL Ltd., Hertfordshire, UK) with the 
accelerating voltage set to 10 kV. 
The mean MPs diameter and size distribution were measured using a Coulter LS230 
particle size analyser (Beckman, UK). MPs were suspended in HPLC grade water, 
under stirring conditions. Size distribution data was collected after achieving an 
obscuration value of 8 – 12%. 
The zeta potentials of the MPs was measured using NanoZS instrument (Malvern, 
UK) in PBS buffer of various pH values (3, 5 & 7). 
2.3 MPs characterization: Determination of protein loading (loading efficiency) 
Measurement of protein content in the MPs was conducted as previously described 
[49, 50] (modified from a technique proposed by Sah [51] and Morita et al. [52]). 10 
mg of PLGA MPs were added to 750 μl DMSO and shaken at room temperature for 
one hour; 2150 μl of 0.02% (w/v) SDS in 0.2 M NaOH was then added and incubated 
for one hour at room temperature. The Micro BCA protein assay kit was used to 
measure the total protein content and compared against a freshly generated 
standard curve of P21mR8R. 150µL sample volume was mixed with 150µL BCA 
working reagent and incubated at 37ºC for 2 hours. Absorbance at 562nm was then 
measured using a plate reader (Infinite M200, Tecan UK Ltd., Reading, UK). 
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2.4 MPs characterization: GET protein release  
30 mg MPs were resuspended in 1 ml Growth media (GM) or HBSS. Samples were 
rocked on a 3D shaker (Gyrotwister, Fisher Scientific UK Ltd) at 5 rpm in a 
humidified incubator at 37°C. At defined time points, samples were centrifuged and 
the supernatant was removed from the MPs and replaced with fresh GM or HBSS. 
The supernatants were assayed for GET and total protein content using fluorometric 
analysis for mRFP1 (excitation: 584 nm; emission: 620 nm; GM samples) and µBCA 
assay kit (HBSS samples). Released protein contents were compared against 
freshly generated standard curve of P21mR8R. 
2.5 Cell Culture 
NIH3T3 mouse fibroblast cells were maintained in Growth Media (GM; DMEM with 
10% (v/v) foetal calf serum (FCS; Sigma) media supplemented with 2mM L-
glutamine, 100 units/ml penicillin and 100 μg/ml streptomycin). Cells were 
maintained in a humidified tissue-culture incubator at 37°C and with 5% CO2 
atmosphere. 
2.6 GET peptides stability assessment 
GET peptide stability in different pH conditions was evaluated. The pH of cell culture 
media was adjusted (pH 3, 5 & 7) using one of the following solutions; 1M glycolic 
acid, 1M glycolic acid, 1M acetic acid, 1M phosphoric acid, 1M hydrochloric acid and 
1M sulfuric acid. 200µg/ml P21mR8R (with or without L-Histidine; 200µg/ml) solution 
was prepared and incubated at 37ºC. At defined time-points, samples were taken 
and diluted 1:10 in fresh cell culture media to neutralise the sample to pH 7.2. 
Protein was then transduced into cells by addition to pre-plated NIH3t3 cells. 
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2.7 GET peptides transduction activity 
Protein transduction activity was evaluated using pre-plated NIH 3t3 cells, as 
previously described [5]. Briefly, 1 x 105 cells/well (in 24-well plates) were plated and 
attached for 4 hours, culture media was then replaced with the media containing 
P21mR8R protein (protein released from MPs (section 2.4) or protein samples from 
stability test (section 2.6)). After 18 hours, cells were washed with PBS, trypsinized 
and fixed in 4% (w/v) PFA for flow cytometry analysis. 
2.8 GET peptides extraction from PLGA MPs using acetone precipitation 
Protein transduction activity was evaluated after the manufacturing process of PLGA 
MPs. This was done to test the effect of PLGA MPs manufacturing process on 
protein activity. Known quantity of MPs were vortexed with cold acetone and 
incubated for 1 hour at -20 ºC. The solution was then centrifuged at 12,000g for 10 
minutes. The acetone was then removed, and the pellet was allowed to dry from the 
remaining acetone. Growth media was then added to the protein pellet. The protein 
activity was evaluated by adding the protein to plated NIH 3t3 cells, as mentioned in 
section 2.7.  
2.9 GET peptides interaction with blank PLGA MPs 
Known quantities of P21mR8R were mixed with blank PLGA MPs, for 30 minutes at 
37ºC in 1ml PBS. The solution was centrifuged (10,000 g for 10 mins) and the free 
P21mR8R quantity in the supernatant was measured using fluorometric analysis for 
mRFP1 (excitation: 584 nm; emission: 620 nm). 
2.10 GET peptides interaction with PLGA degradation product 
GET peptides interaction with PLGA degradation products was tested by suspending 
blank PLGA MPs in media for one week at 37ºC. The solution was centrifuged 
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(10,000 g for 10mins) to collect PLGA degradation products in the supernatant. The 
supernatant was mixed with P21mR8R and different quantities of L-Histidine 
(P21mR8R : L-Histidine ratios were 1:0, 1:0.1, 1:0.25, 1:0.5 & 1:1). Protein was then 
transduced into cells by addition to pre-plated NIH3t3 cells as detailed in section 2.7. 
2.11 Flow Cytometry and Microscopy 
Fixed cells were analysed on a Beckman Coulter Astrios EQ Flow Cytometer using 
green laser (561 nm). (20,000 cells; gated on live cells by forward/side scatter). 
Median fluorescence was used for statistical analyses with background from un-
transduced cells subtracted and values were then calculated in ratio to the 
experimental control. For microscopy, cells were imaged with fluorescence 
microscope using a TRITC filter (Leica DM IRB). 
2.12 Gel Electrophoresis 
For determination of protein molecular weights after incubation in media of various 
pH values, sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) using Novex 10% Tris-Glycine mini protein gel (Invitrogen) was applied 
following manufacturer’s instructions. Gels were stained with Coomassie blue 
(Invitrogen) and de-stained before imaging. 
 
2.13 Statistical Analysis 
Statistical analysis was carried out using GraphPad Prism (version 6). The statistical 
significance was determined using one way ANOVA with Sidak post hoc test. 
Results were considered significant at p<0.05, mean values are given plus or minus 
the standard deviation (SD). 
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3. Results 
3.1 Fabrication of porous high-encapsulation PLGA MPs 
We fabricated PLGA MPs using an optimised S/O/W double emulsion process and 
encapsulated a GET-tagged fluorescent reporter (P21mR8R) [5] (Figure 1A). The 
process was optimised without employment of homogenizer, as our results showed 
loss of protein transduction activity upon homogenisation (i.e. homogenised protein 
at 9000rpm for 2 minutes showed a relative transduction activity of 13% ± 5.2% 
compared to non-homogenised protein). 
MPs prepared using the S/O/W methodology showed spherical structure with 
smooth, non-porous surface (Figure 1B). The mean diameter of these MPs was 45.2 
± 9.7 µm, with average loading efficiency of 73.2 ± 7.6 % (Figure 1 C&D). We 
hypothesized that porous MPs will result in accelerated protein release from MPs. It 
was known that addition of PBS during MPs fabrication would produce porous MPs 
[53]. As predicted PBS addition resulted in porous structure of the MPs (Figure 1B). 
The mean diameter for these MPs found to be 41.5 ± 10.5µm, with average loading 
efficiency of 65.7% (Figure 1 C&D). PBS addition therefore did not significantly affect 
MPs size or encapsulation efficiency. Therefore we created GET-encapsulated MPs 
(with high encapsulation efficiency) which can be engineered to be porous by simple 
addition of PBS during fabrication.  
3.2 Porous MPs allow sustained release of GET proteins 
We next assessed the cumulative protein release from P21mR8R-containing MPs 
(Figure 2 A&B) for the previously mentioned formulations (Figure 1). Protein release 
was quantified by two methods, biochemically using µBCA assay 
(spectrophotometry) and intensity of the released mRFP1 fluorescence (fluorometry). 
Non-porous PLGA MPs showed an initial burst release (around 20% ± 4.2  of total 
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loaded) within the first day, with no further detectable protein was released even with 
a further 21 days of incubation (µBCA detection limit is 0.5µg/ml) (Figure 2 A&B) (the 
release is expected to continue after day 21 as previously shown [50]).  It was 
expected that the porous formulations would have more efficient protein release. The 
release profile obtained from MPs with PBS-created pores (PLGA-PBS) showed a 
similar burst release (on day 1, 18% ± 3.7) but this level was retained producing a 
continuous protein release over 5-7 day period. More than 90% ± 7.9, cumulative 
release, could be achieved after 10 days (Figure 2 A&B), after which little further 
protein was released. We were therefore able to demonstrate a controlled release of 
P21mR8R from porous-MP (PLGA-PBS) formulations. 
 
3.3 GET transduction activity is inhibited during sustained release 
formulations 
We showed efficient release of GET proteins over a 7 day period using S/O/W 
fabricated PLGA porous-MPs (PLGA-PBS). Next we aimed to demonstrate the 
released GET protein retained its full transduction activity by comparing released 
P21mR8R to non-encapsulated controls. Released GET-protein (from porous PLGA-
PBS MPs) was collected over the 7 day time course and was incubated with NIH3t3 
cells to assess internalisation and transduction ability. Importantly we compared 
transduction to non-encapsulated controls diluted to the same final concentration. 
Incubated cells were then evaluated for transduction by fluorescence microscopy 
and flow cytometry analyses (Figure 2 C-E).  
Fluorescent microscopy showed significant GET protein internalisation for samples 
released from PLGA-PBS MPs in the first day (Figure 2C). Flow cytometry results 
showed that the protein released at the first day has a relative transduction activity 
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above 85% ± 12.3 (Figure 2 D&E). However, GET-protein released from these MPs 
(PLGA-PBS) showed gradual loss of protein transduction activity with relative 
transduction activity below 35% ± 4.7 at day 7 (Figure 2E). Overall, activity of the 
fully released GET-protein over the 7 days is therefore significantly inhibited (with 
only ~51% ± 9.5 transduction is realised verses the non-encapsulated P21mR8R), 
and less than 35%± 4.7 activity towards the end of the release profile. We 
hypothesized it may be possible that the released P21mR8R protein was interacting 
with PLGA or its degradation products, inhibiting the interaction with cell membranes 
and endocytosis. This inhibitory phenomenon would restrict the use of GET-protein 
in this controlled release system and we believed further optimisation was required 
to improve the relative transduction activity from released protein. 
3.4 Co-encapsulation of L-Histidine during fabrication of porous PLGA MPs 
It is known that acidic microenvironment results from PLGA degradation can affect 
protein stability [19, 54]. It was suggested that P21mR8R can be affected by either 
the acidic microenvironment during controlled release from PLGA or its transduction 
activity was being inhibited by interaction with PLGA or its degradation products. We 
hypothesized that addition of a proton-scavenger (such as L-Histidine) may improve 
the activity of the released protein from MPs. Our hypothesis was that the carboxyl 
groups liberated from PLGA degradation may interact with the positively charged 
GET peptides, inhibiting transduction. L-Histidine, a positively charged amino acid at 
pH <6, is expected to neutralize the acidic pH and act as a scavenger and bind to the 
carboxyl groups. We therefore generated porous PLGA MPs containing L-Histidine 
(0.25% w/w). L-Histidine MPs prepared with addition of PBS, have the average 
diameter and loading efficiency of 42.3 ± 9.1µm and 67.4 ± 6.3 % respectively. Using 
SEM and particle sizing, we were able to determine that incorporation of L-Histidine 
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did not affect the morphology, size and the loading efficiency of MPs, as shown in 
the representative SEM images (Figure 1B) and size distribution and loading 
efficiency results (Figure 1 C&D), respectively. This demonstration was important as 
we showed it is possible to add excipients (such as L-Histidine) directly to the 
formulation without affecting MPs physical properties. 
3.5 L-Histidine has no effect on sustained release of GET proteins from porous 
MPs 
To confirm that the same release kinetics are retained with incorporation of L-
Histidine we repeated the analyses of P21mR8R release over time. Incorporation of 
L-Histidine to the formulation (PLGA-PBS-Histidine) did not change the release 
profile significantly (Figure 2 A&B), MPs showed gradual and continuous release 
similar to plain porous-MPs (PLGA-PBS), with around 83% ± 9.8 cumulative release, 
after 10 days. We were therefore able to demonstrate a controlled release of 
P21mR8R from porous-MP (PLGA-PBS) formulations with or without the addition of 
a potential excipient (L-Histidine; PLGA-PBS-Histidine). 
3.6 L-Histidine protects GET transduction activity in sustained release 
formulations 
We next assessed whether the addition of L-Histidine to MPs can improve the 
transduction activity of the released GET-protein (PLGA-PBS-L-Histidine 
formulations). Flow cytometry results showed that the protein released at the first 
day has a relative transduction activity above 85% ± 8.6, similar to that of PLGA-PBS 
MPs (Figure 2 D&E). However, GET-protein released from PLGA-PBS-Histidine MPs 
retained its relative transduction activity above 80% on all studied time points (Figure 
2E). This observation clearly demonstrates that L-Histidine addition to porous-PLGA 
MPs significantly prevents the loss of GET transduction activity during protein 
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release. The mechanism by which L-Histidine helps retain GET transduction activity 
could be through negating internal acidic pH within the degrading MPs, or there 
could be direct interaction between PLGA or its degradation products and P21mR8R 
which would be inhibited in presence of L-Histidine. 
3.7 Understanding the mechanism of L-Histidine activity to promote GET 
transduction in controlled release formulations. 
3.7.1 GET activity is not influenced by MPs fabrication 
We initially aimed to ascertain if the fabrication process itself or the release 
environment was the inhibitory factor for GET transduction activity post-release. 
Initially we formulated MPs and extracted the GET protein directly after fabrication 
using acetone. Acetone extraction did not affect GET protein activity and was an 
effective way to rapidly recover encapsulated P21mR8R from MPs. The results 
showed that the relative transduction activity of the protein extracted from MPs is 
around 88.3 ± 9.3%, compared to fresh protein. This clearly demonstrated that the 
manufacturing process is not affecting the GET peptides activity but the release 
process was inhibiting protein transduction. 
3.7.2 GET activity is inhibited by PLGA degradation products at neutral pH 
We identified the controlled release as the inhibitory process on GET transduction 
activity. We next assessed any possible interaction between the GET peptides and 
the PLGA degradation products and its impact on GET peptides transduction activity. 
When PLGA degrades by hydrolysis it releases carboxyl group containing molecules 
which could interfere with GET transduction activity. We studied the GET peptides 
activity in presence of PLGA degradation products collected from PLGA degradation 
in media. The pH of the media upon GET peptides addition was around 6.0 ± 0.2. 
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Fluorescence microscopy showed that there was very low transduction activity for 
P21mR8R added to cells with degraded PLGA supernatants (Figure S1 A), flow 
cytometry showing a relative transduction activity of around 34% ± 8.9 (Figure S1 B). 
This data therefore confirms that during controlled release PLGA degradation 
products will have an inhibitory effect of GET protein transduction activity. 
3.7.3 L-Histidine prevents GET peptide interaction with PLGA degradation 
products 
The previous results showed that PLGA degradation product is inhibiting GET 
peptides activity (Section 3.7.2), in order to assess L-Histidine effect on GET-PLGA 
degradation product interaction, the experiment was repeated with various quantities 
of L-Histidine being incorporated with P21mR8R. Addition of L-Histidine resulted in 
enhanced transduction activity, as the L-Histidine is expected to interact with the 
carboxylic group-containing PLGA degradants. Samples of 1:0.1 ratio (P21mR8R:L-
Histidine) showed enhanced transduction activity, compared to samples with no L-
Histidine (Figure S1 A), however, only around 55% ± 4.3 transduction activity could 
be achieved (Figure S1 B). For samples prepared with addition of L-Histidine > 25% 
of the P21mR8R quantity, fluorescent microscopy and flow cytometry results showed 
comparable protein transduction activity at all time points (Figure S1 A), with relative 
transduction activity above 80% could be achieved (Figure S1 B). This clearly 
demonstrates the role of L-Histidine in maintaining the activity of GET peptides in 
presence of PLGA degradation products. 
3.7.4 GET peptides interact directly with PLGA MPs at neutral pH 
PLGA MPs are negatively charged [55]. Blank PLGA MPs charge was measured at 
various pH values (3, 5 & 7). The results showed that the PLGA MPs are negatively 
charged at all studied pH values (table S1). As GET peptides are positively charged 
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[5] (the calculated isoelectric point (pI) for P21 and 8R is 10.9 and 12.9 respectively 
(table S2) [56]) it is expected that P21mR8R interacts with the negatively charged 
PLGA MPs. In order to evaluate the interaction between the GET peptides and 
PLGA MPs, we assessed the direct interaction between P21mR8R and PLGA MPs 
in a pulldown assay. P21mR8R was mixed with various quantities of blank PLGA 
MPs. After incubation, MPs were removed by centrifugation and the loss of soluble 
P21mR8R (binding to PLGA) was assessed by fluorometry. This assay was 
designed to determine if there was any direct interaction of P21mR8R with intact 
PLGA polymer. The results demonstrated that at neutral pH less P21mR8R protein 
remains free in the supernatant with increasing MPs quantities (i.e. only 20% of the 
protein quantity could be detected when mixed with 25mg of PLGA MPs) indicating 
that the P21mR8R interacts with PLGA polymer in the MPs (Figure S2 A). Many 
interaction types can be associated in P21mR8R binding to PLGA MPs, but the main 
type to control the interaction, in presence of positively charged peptides, is 
electrostatic interaction [57]. Hydrophobic interaction might be affecting the 
adsorption of P21mR8R on the surface of PLGA MPs due to the fact that the PLGA 
is hydrophobic. However this interaction is considered negligible [46, 48, 57]. 
3.7.5 Free Carboxyl groups inhibit GET/PLGA interaction. 
We have shown that P21mR8R is interacting with PLGA MPs at neutral pH, 
however, as PLGA degrades it releases lactic and glycolic acid molecules which 
decrease the pH. We hypothesized that rather than pH disrupting the 
P21mR8R/PLGA interaction that the presence of carboxyl groups may affect 
PLGA/P21mR8R interaction. We repeated our interaction assay at lower pH value 
(~3). 
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Interestingly, at pH 3, all the protein remained in the supernatant, and there was no 
significant interaction with the PLGA MPs (Figure S2 A). This was unexpected as we 
hypothesized that in a low pH microenvironment (which would be similar to that 
generated in hydrolysing PLGA during the release process) that P21mR8R would 
still interact with PLGA polymers, as our results suggested that the PLGA will be 
negatively charged at this pH (table S1). This observation was important, we 
demonstrated that P21mR8R can directly interact with PLGA, but that this can be 
disrupted by the presence of carboxylic acid.   
It was imperative that we counteract the negative influence of carboxylic acid binding 
of P21mR8R if PLGA polymer was to be used for successful controlled release of 
GET peptides. We therefore tested excipient addition to this assay aiming to disrupt 
P21mR8R interaction with carboxylic groups. Applying the same conditions in 
presence of L-Histidine resulted in GET peptides interaction with MPs at neutral pH 
(Figure S2 B), with only around 20% of the protein quantity could be detected, which 
is expected as the L-Histidine is not positively charged at this pH. Interestingly, at pH 
3, the positively charged L-Histidine appeared to act as a scavenger for the carboxyl 
groups from the added carboxyl groups and P21mR8R retained its ability to interact 
with the negatively charged PLGA MPs. We therefore conclude that P21mR8R can 
interact with both PLGA directly (most likely electrostatically) and also with carboxylic 
groups (which can disrupt the PLGA interaction). By using L-Histidine we could 
retain P21mR8R/PLGA interaction, most likely through a sequestering of free 
carboxylic acid groups by positively charged L-Histidine (Figure S2 B).  
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3.8 GET peptides stability in various pH conditions simulating PLGA MP 
microenvironment 
3.8.1 GET peptides activity is inhibited in presence of carboxyl acid group  
In order to fully understand the mechanism by which GET-protein transduction 
activity is inhibited post-release, we aimed to model the conditions experienced by 
the P21mR8R protein inside the MPs without the fabrication. During protein release 
the degrading PLGA is hydrolysed, releasing glycolic and lactic acid (carboxyl group 
containing molecules) into the microenvironment and it is progressively acidified.  To 
test the effect of such acid groups and the overall pH have on retention of GET-
transduction activity, P21mR8R was incubated in cell culture media of various pH 
values (3, 5 & 7), pH adjusted using either 1M lactic acid, 1M glycolic acid or 1M 
acetic acid solutions. After incubation, samples were neutralized by dilution and 
protein transduction activity was evaluated, using NIH 3t3 cells (fluorescence 
microscopy and flow cytometry). The neutralization process is important as all 
proteins were transduced into cells at the same neutral pH (pH 7.2), therefore this 
directly assesses the effect of pH during the incubation, with transduction as a 
readout of functionality. Protein storage, sampling and transduction into cells were 
done as diagrammed in Figure S3 A. Fluorescence microscopy showed significant 
protein internalization, for samples stored at pH 3, at day 1 compared to controls, 
however, protein transduction was undetectable for day 7 samples (Figure 3 A, 
Figure S4 A) this can be seen in samples of all studied solutions; lactic acid, glycolic 
acid and acetic acid. Flow cytometry results confirmed a loss in transduction for day 
7 samples (Figure 3 C & D, Figure S4 E), and gradual loss of relative transduction 
activity over the time-points, reaching values below 30% at day 7 (Figure 3 C & D, 
Figure S4 E). Interestingly, fluorescent microscopy showed protein transduction for 
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samples stored at pH 5 & 7 at all studied time points (Figure 3 C & D, Figure S4 E). 
For pH 5, flow cytometry results confirmed this with relative transduction activity 
above 80% of non-treated controls at all studied time points. For pH 7, flow 
cytometry results showed minimal decrease in relative transduction activity with 
values around 60% at all studied time points (Figure 3 C & D, Figure S4 E). 
Importantly both pH 5 and 7 data shows high levels of activity is retained, even with 
extended culture (7 days). This is unlike activity seen at pH3 samples which is 
progressively decreased until very low levels are left at day 7 (~25%). Therefore high 
concentration carboxylic acid inhibits the activity of GET transduction over time. 
Importantly this is not due to stability of the protein as fluorescence of the P21mR8R 
was not affected by these conditions. 
3.8.2 L-Histidine prevents carboxylic acid-mediated inhibition of GET 
transduction 
To determine if L-Histidine could promote GET-protein transduction in high 
carboxylic acid/low pH as for MPs-released protein, we repeated the pH incubation 
experiments in the presence of L-Histidine. As before, protein was stored in cell 
culture media of various pH values (3, 5 & 7); adjusted using either 1M lactic acid, 
1M glycolic acid or 1M acetic acid. Unlike P21mR8R alone, L-Histidine (200µg/ml) 
containing samples (either for fluorescence microscopy and flow cytometry analyses) 
did not lose P21mR8R transduction activity for all the studied pH conditions including 
those at pH 3 (Figure 3 B – D, Figure S4 F). Protein relative transduction activity was 
above 60% for all the studied conditions (Figure 3 C & D, Figure S4 F) and therefore 
it was clear that the presence of L-Histidine during incubation prevented the loss of 
GET transduction activity. 
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3.9 L-Histidine dose is important to preserve GET transduction  
Our previous analyses employed one concentration (200µg/ml) of L-Histidine to 
negate the negative effect of carboxylic acid on GET peptides transduction. Next we 
assessed the dose requirement for this activity. P21mR8R (200µg/ml) with different 
quantities of L-Histidine (0 – 200µg/ml) was incubated at pH3 in acetic acid-adjusted 
cell culture media. Fluorescence microscopy and flow cytometry demonstrated 
gradual loss of protein transduction activity for samples with no L-Histidine (Figure 
4A & B). Samples containing 20µg/ml L-Histidine showed enhanced transduction 
activity, compared to samples with no L-Histidine (Figure 4A & B), however,  only 
50% transduction activity could be achieved after 3 days (Figure 4C). For samples 
prepared with addition of > 50µg/ml of L-Histidine, fluorescent microscopy and flow 
cytometry results showed comparable protein transduction activity at all time points 
(Figure 4 A&B), with relative transduction activity above 60% could be achieved in all 
time points (Figure 4C). Therefore 50µg/ml L-Histidine was sufficient to mediate the 
maximum effect to negate the inhibitory effect of carboxylic acid. This represents 
25% of the P21mR8R quantity. 
4. Discussion 
Optimized porous PLGA MPs for efficient GET-protein controlled release. GET 
reporter protein, P21mR8R, release from PLGA MPs prepared using S/O/W was 
found to be very low, with ~20% released as a burst in the first day, and no further 
release up to 21 days (released protein quantities below detection limit were 
eliminated). We accelerated the protein release by incorporating PBS during the 
formulation. PBS worked as a porogen, which increased MPs porosity and 
generated channels within and on the surface of the MPs [53]. These pores 
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increased the release to above ~90% in 7 days period. Importantly, PBS addition did 
not change the protein encapsulation efficiency nor the MP size, which provides a 
robust method to deliver GET proteins over a 7 day period. It is worth noting that the 
release study was performed for up to 21 days. A previous study within our group 
[50] showed a similar formulation began another lower phase of release after 21 
days until day 35. Our aim was to develop a delivery system to release the majority 
of contents over 7 days (~90% release) using PBS as a porogen, however it is likely 
that lower protein levels are still being released but this is either below the sensitivity 
of detection or after the 21 day sampling period. 
 
GET peptides stability in PLGA. It was clear that P21mR8R was stable upon 
extraction and initial release from PLGA MPs. Therefore we expected the released 
protein would retain transduction activity over the release period. To investigate this, 
P21mR8R was encapsulated in PLGA MPs, the released quantity was monitored 
and its activity to transduce into cells assessed. The results were compared to 
experimental control (equivalent fresh protein quantity). The results showed loss of 
protein transduction activity with time (i.e. the protein released at the first day 
showed 80% activity, while the protein released at day 7 was below 30%) (Figure 2). 
The protein could be detected using fluorometric analysis, which suggests that the 
fluorescent part of the protein (mR) was intact but the GET peptides, enhancing the 
protein internalization in the cells, were no longer functional. This may be attributed 
to protein hydrolysis (i.e. detachment of the GET peptides (P21 & 8R) from the 
fluorescent part (mR)), or interaction between the negatively charged PLGA (or it’s 
degradation product) with the positively charged GET peptides, which would prevent 
the interaction between GET peptides and cell membrane heparan sulfate. 
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GET peptides interaction with PLGA and its degradation products. The possible 
interaction between GET peptides and PLGA MPs was assessed, the results 
showed that the positively charged P21mR8R is interacting with the negatively 
charged PLGA MPs. Moreover, the P21mR8R showed loss of transduction activity 
when exposed to PLGA MPs degradation products. 
Simulating GET peptides instability in the polymer. During protein release, acidic 
microenvironment usually develops with PLGA MPs as a result of poly ester 
hydrolysis, this results in carboxylic acid accumulation [19]. To test the effect of this 
acidic environment on protein transduction activity, we simulated GET peptides 
instability in PLGA microclimate. P21mR8R was exposed to different conditions of 
pH (3, 5 & 7) for one week. Of the studied conditions, only highly acidic conditions 
(pH 3) showed loss of protein transduction activity. Gel electrophoresis results 
showed that P21mR8R degraded at these conditions (figure S11). The results 
showed gradual loss of P21mR8R transduction activity (Figure 3), which was 
experienced during protein release from PLGA MPs. On the other hand, samples 
stored at pH ≥ 5, protein relative transduction activity was above 60% at all studied 
time points (Figure 3). The common factor between the simulating study and the 
PLGA MPs is the carboxylic acid accumulation in the media. The same protein 
behaviour was observed in both studies, which confirms that GET peptides are 
affected by carboxylic acid. 
GET peptides stability in presence of other acids. GET peptides stability in acidic 
conditions was studied using different acids (Weak acids: lactic acid, glycolic acid, 
acetic acid & phosphoric acid. Strong acids: hydrochloric acid (HCl) & sulfuric acid). 
The results showed that GET peptides gradually lose the activity in presence of 
weak acids, but immediately in presence of strong acids. 
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Developing a hypothesis for mechanism of instability of encapsulated GET 
peptides. Low pH usually develops in PLGA MPs as a result of accumulation of 
acidic degradants. From our simulation studies, a highly acidic environment (~pH 3) 
was needed to inactivate the protein transduction activity. The results suggested that 
the negatively charged carboxylic acid groups, which results from PLGA 
degradation, will interact with the positively charged GET peptides, preventing them 
from binding to the cell membrane and consequently preventing protein 
internalization. A schematic showing the proposed interaction/mechanism between 
GET peptides and the carboxyl group liberated during PLGA degradation is shown in 
Figure 5 (A & C). 
Developing a stabilization approach using L-Histidine. Since GET peptides 
activity is compromised in presence of carboxylic acid group, the intended approach 
is to scavenge this group by adding a molecule that will compete with the protein in 
interaction with carboxylic acid. GET peptides are positively charged, and it is 
expected that they will interact with the negatively charged molecules. L-Histidine is 
positively charged amino acid at pH ≤6. L-Histidine is expected to compete with the 
P21mR8R in interacting with the carboxylic group. Consequently, to test whether the 
L-Histidine could enhance GET peptides activity at low pH, we have repeated the pH 
simulation study, in presence of L-Histidine (Figure 3). L-Histidine was added in 
quantities that will not affect the solution pH (Figure S8). As expected, P21mR8R 
showed enhanced transduction activity, in presence of L-Histidine, compared to 
samples without L-Histidine. Moreover, P21mR8R maintained its structure in 
presence of L-Histidine at low pH (figure S11). Various pH conditions were studied (5 
& 7), with and without L-Histidine, and the same protein behaviour was noticed, 
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which suggests that the L-Histidine works at low pH only, due to its charge, and the 
presence of L-Histidine along with the protein, at higher pH, will not alter its activity. 
L-Histidine works in presence of weak acids but not strong acids. Results 
showed that L-Histidine can negate the effect of weak acids on GET peptides but not 
strong acids. This may be due to the fact that strong acids are 
denaturing/deaminating GET peptides.  
L-Histidine quantity is critical in maintaining GET peptides activity. In order to 
study the effect of the L-Histidine quantity on the protein transduction activity, 
different quantities of L-Histidine were examined (0 – 200 µg/ml). The maximum 
protein activity could be achieved at ratios higher than 1:0.25 w/w (protein: L-
Histidine).  
PLGA MPs containing L-Histidine as a stabiliser for GET peptides. In order to 
validate our findings on actual PLGA MPs, L-Histidine was encapsulated with 
P21mR8R inside PLGA MPs. Protein release was monitored, with protein release 
behaviour comparable, with and without L-Histidine, exhibiting a burst release of 
around 20%, then continuous and complete release up to 7 days. The released 
protein transduction activity was significantly higher for MPs prepared with addition 
of L-Histidine, compared to MPs without L-Histidine. Protein relative transduction 
activity was above 80% at day 7, with addition of L-Histidine, compared to 30% 
without L-Histidine. A schematic showing L-Histidine role in maintain GET peptides 
transduction activity is shown if Figure 5 (B & D). 
5. Conclusion 
A robust method of fabricating protein-loaded MPs was optimized, using S/O/W 
emulsion technique. L-Histidine was used as a stabiliser to maintain the GET system 
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activity during release from MPs. Incorporation of L-Histidine in PLGA MPs did not 
change the protein release profile. The presence of L-Histidine in the MPs effectively 
enhanced the protein stability in acidic conditions caused by degradation of PLGA. 
The maintenance of the protein stability by incorporating L-Histidine in PLGA MPs is 
strong evidence supporting the hypothesis that the GET peptides are interacting with 
acidic degradation products of the PLGA and the addition of L-Histidine is a 
successful strategy. 
The advantage of this delivery system is to provide localized release of GET-tagged 
therapeutic molecules with minimised risk of systemic dosing that may lead to non-
targeted activity. This delivery technology has potential to be valuable in the 
controlled delivery of various potent therapeutic molecules, coupled with GET 
peptides, which can be used for drug delivery and regenerative medicine 
applications. 
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10. Figure Legends 
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Figure 1. MP manufacturing process and characterization; SEM and size 
analyses. MPs were fabricated (15% (w/v) PLGA 50:50), loaded with P21mR8R 
(0.5% (w/w)), mixed with different quantities of PBS and L-Histidine (1) No PBS, no 
L-Histidine. (2) 0.1% (w/w) PBS, no L-Histidine. (3) 0.1 % (w/w) PBS, 25% (w/w) L-
Histidine. (A) Schematic showing the solid-in-oil-in-water double emulsion method of 
PLGA MPs manufacturing (B) SEM analyses for MPs (scale bars represent 50µm on 
top images, and 10µm on bottom images). (C) Summary of size characterization and 
corresponding loading efficiencies (n = 3). (D) Representative size distribution of the 
different PLGA MPs formulation, (black line) No PBS, no L-Histidine, (dashed grey 
line) 0.1% (w/w) PBS, no L-Histidine, (dashed black line) 0.1 % (w/w) PBS, 25% 
(w/w) L-Histidine. 
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Figure 2. In vitro release profiles of P21mR8R from PLGA MPs (pH 7.4 at 37 ºC) 
and transduction activity of the released P21mR8R. MPs were prepared using 
S/O/W method (15% (w/v) PLGA), loaded with P21mR8R (0.5% (w/w)), mixed with 
different quantities of PBS and L-Histidine (see Figure 1 for MPs characteristics). (A) 
Protein was quantified using fluorescence intensity (B) protein was quantified using 
Micro BCA assay kit.(▲) No PBS, no L-Histidine. (♦) 0.1% (w/w) PBS, no L-Histidine 
(■) 0.1 % (w/w) PBS, 25% (w/w) L-Histidine. Error bars indicate SD (n = 3). 
Transduction activity of the released protein was assessed by addition to plated 
NIH3t3 cells. This study was performed for two different formulations PLGA-PBS and 
PLGA-PBS-Histidine. (C) Fluorescence microscopy images of the NIH3t3 cells 
treated with the sampled P21mR8R (Scale bar 10μm). (D) Flow cytometry 
histograms showing cellular uptake of P21mR8R after application of the samples to 
NIH3t3 cells. The red histograms are the P21mR8R samples, while the black 
histograms are the experimental control. (E) Relative biological activity of the 
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sampled P21mR8R. Protein transduction activity was compared to the experiment 
control. Error bars indicate SD (n = 3). * is p<0.05, ** is p<0.01. 
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Figure 3. GET-peptide stability at various pH values mimicking the PLGA 
microenvironment. P21 mR8R stability in cell culture media of various pH values 
(3, 5 & 7), with and without L-Histidine. pH was adjusted using either 1M lactic acid 
solution or 1M glycolic acid solution. Protein sample was transduced into cells by 
addition to plated NIH3t3 cells. Fluorescence microscopy images of the NIH3t3 cells 
treated with the protein samples. (A) P21mR8R only and pH adjusted using 1M lactic 
acid or 1M glycolic acid solutions (Scale bar 10μm). (B) P21mR8R and L-Histidine 
and pH adjusted using 1M lactic acid or 1M glycolic acid solution (Scale bar 10μm). 
Relative transduction activity of the samples (C) P21mR8R with and without L-
Histidine and pH adjusted using 1M lactic acid solution (D) P21mR8R with and 
without L-Histidine and pH adjusted using 1M glycolic acid solution. Protein 
transduction activity was compared to the experiment control. Error bars indicate SD 
(n = 3). * is p<0.05, ** is p<0.01. 
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Figure 4. Dose of L-Histidine required to promote GET-peptide activity. Effect of 
different quantities of L-Histidine on P21mR8R stability upon storage in cell culture 
media of pH 3 (pH was adjusted using 1M acetic acid solution). 200µg/ml P21mR8R 
solution was prepared with various quantities L-Histidine (0 – 200µg) and stored at 
37ºC. A sample was taken from each solution, at defined time points, and diluted 
1:10 in fresh cell culture media. Protein was then transduced into cells by addition to 
plated NIH3t3 cells. (A) Fluorescence microscopy images of the NIH3t3 cells treated 
with the sampled P21mR8R (Scale bar 10μm). (B) Flow cytometry histograms 
showing cellular uptake of P21mR8R after application of the samples to NIH3t3 cells. 
The red histograms represent P21mR8R samples taken at day 1, while the grey 
histograms represent day 7 samples, black histograms are the experiment control. 
(C) Relative transduction activity of the sampled P21mR8R. Protein transduction 
activity was compared to the experiment control. Error bars indicate SD (n = 3). * is 
p<0.05. 
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Figure 5. Schematic for hypothesis of GET peptides interaction with Carboxyl 
groups and L-Histidine. Interaction between GET peptides released from MPs and 
cells in presence of carboxyl groups resulted from PLGA degradation, with and 
without L-Histidine. (A) pH 7 without L-Histidine. (B) pH 7 with L-Histidine. (C) pH 3 
without L-Histidine. (D) pH 3 with L-Histidine. 
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Supplemental Information: 
Controlled release of GAG-binding Enhanced Transduction (GET) peptides for 
sustained and highly efficient intracellular delivery 
Results 
1. GET peptides activity is inhibited in presence of other acidic groups  
In order to study the GET peptides stability in presence of other acidic groups, GET 
peptides were incubated, for 7 days, in media of various pH values (3, 5 & 7), the pH 
was adjusted using different solutions, 1M phosphoric acid (weak acid), 1M 
hydrochloric acid (HCl) (strong acid), or 1M sulfuric acid (strong acid). The 
experiment schematic is shown in figure S5 A. The collected samples were then 
applied to plated NIH 3t3 cells and cellular uptake of GET peptides was evaluated 
using fluorescence microscopy and flow cytometry. Fluorescence microscopy 
showed significant protein internalisation, for samples stored at pH 3, at day 1, for 
samples stored in media containing phosphoric acid. However, protein transduction 
was undetectable for day 7 samples (Figure S5 B). Flow cytometry results confirmed 
a loss in transduction for day 7 samples (Figure S5 B), and gradual loss of relative 
transduction activity over the time-points, reaching values below 20% at day 7 
(Figure S5 D & F). Interestingly, fluorescent microscopy showed protein transduction 
for samples stored at pH 5 & 7 at all studied time points (Figure S5 B). Flow 
cytometry results confirmed this with relative transduction activity above 80% of non-
treated controls at all studied time points. This behaviour is comparable to the 
previous obtained results using lactic, glycolic and acetic acid (section 3.8.1). On the 
other hand, fluorescent microscopy for samples stored at pH 3 media containing 
strong acids (hydrochloric or sulfuric acid) showed major loss of GET peptides 
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activity from day 1 (Figures S6 A & S7 A), with relative transduction activity below 
40% (Figures S6 E and S7 E). Samples stored at pH 5 & 7 showed minimal loss of 
activity with relative transduction activity above 60% in all studied time points 
(Figures S6 E & S7 E). 
2. L-Histidine protect GET peptides in presence of weak acid but not 
strong acid 
To determine if L-Histidine could promote GET-protein transduction in presence of 
various acidic groups, we repeated the pH incubation experiments in the presence of 
L-Histidine. As before, protein was stored in cell culture media of various pH values 
(3, 5 & 7); adjusted using either 1M phosphoric acid, 1M hydrochloric acid (HCl), or 
1M sulfuric acid. In presence of phosphoric acid (weak acid) L-Histidine (200µg/ml) 
containing samples (either for fluorescence microscopy and flow cytometry analyses) 
showed comparable P21mR8R transduction activity for all the studied pH conditions 
including those at pH 3 (Figure S5 C, E & G). Protein relative transduction activity 
was above 60% for all the studied conditions (Figure S5 G) and therefore it was clear 
that the presence of L-Histidine during incubation prevented the loss of GET 
transduction activity. On the other hand, L-Histidine did not protect GET peptides at 
pH 3 in presence of strong acids (HCl or sulfuric acid) (Figures S6 B & F and S7 B & 
F), with relative transduction activity below 40% from day 1. 
3. L-Histidine does not neutralize carboxyl group acidity 
In order to clarify why L-Histidine has such profound effect on carboxyl acid-
mediated inhibition of GET transduction, we determined if the addition of L-Histidine 
could neutralize the acidity of the carboxyl acid-containing media. The pH of the 
media after addition of L-Histidine (200µg/ml) was measured in the three studied pH 
conditions (3, 5 & 7). The pH found to be the same, with no significant change 
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(Figure S8). Also, to confirm the quantities of L-Histidine required to neutralize the 
pH we employed, we performed a back titration with L-Histidine. Our titration showed 
that the molar ratio of 1:5 between the acetic acid and L-Histidine is required for 
neutrality. Accordingly, it is very unlikely that the L-Histidine is neutralizing the pH 
conditions in our system, but will work as a scavenger competing with PLGA 
degradation products for GET peptide interaction. 
4. Co-incubation with L-Histidine is required to prevent inhibition of GET 
transduction by carboxylic acid 
In order to assess if the mechanism of L-Histidine was during incubation, or could be 
manifest by its addition post-incubation, we repeated the pH incubation experiments. 
After samples were taken and diluted, 20µg L-Histidine was added and transduction 
activity tested. Fluorescent microscopy showed no protein transduction in the cells 
incubated at pH 3 with or without addition of L-Histidine post-incubation (Figure 
S9A). Flow cytometry confirmed that L-Histidine addition had no effect unless it was 
present throughout the pH incubation (Figure S9 B), with relative transduction activity 
around ~20%. It is therefore likely that L-Histidine prevents P21mR8R/carboxylic 
acid interaction or pH-dependent inhibition of transduction which is a gradual 
process over the 7 days experiment. 
5. Poly-L-Histidine also prevents the inhibition of GET transduction in 
carboxylic acid/low pH conditions 
In order to confirm that other histidine containing molecules can also help prevent 
the inhibition of GET transduction activity from PLGA-MPs release, we assessed if 
Poly-L-Histidine can also mediate this effect. We repeated the pH stability assay with 
the addition of Poly-L-Histidine (200µg/ml). Fluorescence microscopy showed protein 
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internalization in the cells for all pH conditions at all time points containing Poly-L-
Histidine versus a loss of transduction with no excipient (Figure S10 B). Flow 
cytometry data showed gradual loss of protein transduction activity at pH 7 (Figure 
S10 C), with relative transduction activity of around 30% after 7 days (Figure S10 D). 
Protein transduction activity at pH 3 was above 50% at all time points (Figure S10 
D). Protein incubated at pH 5 possessed transduction activity comparable to the 
experimental control (Figure S10 C), with relative transduction activity above 80% at 
all time points. This data therefore concludes that any L-Histidine containing 
excipient may be used to prevent the negative effect of carboxylic acid-mediated low 
pH on transduction.  
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Supplemental Figures: 
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Figure S1. Effect of L-Histidine on GET peptides stability in media contains 
PLGA degradation product. Blank PLGA MPs were left to degrade in media, after 
that P21mR8R was mixed with the media and different quantities of L-Histidine. 
Protein was then transduced into cells by addition to plated NIH3t3 cells. (A) 
Fluorescence microscopy images of the NIH3t3 cells treated with the sampled 
P21mR8R (Scale bar 10μm) and flow cytometry histograms showing cellular uptake 
of P21mR8R after application of the samples to NIH3t3 cells. The red histograms 
represent P21mR8R samples while black histograms are the experiment control. (B) 
Relative transduction activity of the sampled P21mR8R. Protein transduction activity 
was compared to the experiment control. Error bars indicate SD (n = 3). * is p<0.01. 
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Figure S2. GET peptides interaction with blank PLGA MPs at different pH 
conditions with and without L-Histidine. PLGA MPs were suspended in solution 
of different pH values and P21mR8R was then added, the solution was then 
centrifuged and the P21mR8R quantity in the supernatant was measured. (A) 
P21mR8R interaction with various blank PLGA MPs quantity at various pH 
conditions without L-Histidine. (B) P21mR8R interaction with 25mg PLGA MPs at 
various pH conditions in presence of different L-Histidine quantities. Error bars 
indicate SD (n = 3). 
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Figure S3. GET-peptide stability at various pH values mimicking the PLGA 
microenvironment. P21mR8R stability in cell culture media of various pH values (3, 
5 & 7), with and without L-Histidine. pH was adjusted using either 1M lactic acid 
solution or 1M glycolic acid. (A) Schematic of the protein storage and sampling, 
200μg/ml P21mR8R with or without 200μg/ml L-Histidine solution was prepared with 
various pH values (3, 5 &7) and stored at 37ºC. A sample was taken from each 
solution, at defined time points, and diluted 1:10 in fresh cell culture media. Protein 
was then transduced into cells by addition to plated NIH3t3 cells. Flow cytometry 
histograms showing cellular uptake of P21mR8R after application of the samples to 
NIH3t3 cells (B) samples contain P21mR8R and pH adjusted using 1M lactic acid 
solution (C) samples contain P21mR8R and L-Histidine and pH adjusted using 1M 
lactic acid solution (D) samples contain P21mR8R and pH adjusted using 1M 
glycolic acid solution (E) samples contain P21mR8R and L-Histidine and pH 
adjusted using 1M glycolic acid solution. The red histograms represent P21mR8R 
samples taken at day 1, while the grey histograms represent day 7 samples, black 
histograms are the experiment control. 
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Figure S4. GET-peptide stability at various pH values mimicking the PLGA 
microenvironment. P21mR8R stability in cell culture media of various pH values (3, 
5 & 7), with and without L-Histidine. pH was adjusted using 1M acetic acid solution. 
A sample was taken from each solution, at defined time points, and diluted 1:10 in 
fresh cell culture media. Protein was then transduced into cells by addition to plated 
NIH3t3 cells. (A) Fluorescence microscopy images of the NIH3t3 cells treated with 
the samples contain P21mR8R (Scale bar 10μm). (B) Fluorescence microscopy 
images of the NIH3t3 cells treated with the samples contain P21mR8R and L-
Histidine (Scale bar 10μm). Flow cytometry histograms showing cellular uptake of 
P21mR8R after application of the samples to NIH3t3 cells (C) samples contain 
P21mR8R (D) samples contain P21mR8R and L-Histidine. The red histograms 
represent P21mR8R samples taken at day 1, while the grey histograms represent 
day 7 samples, black histograms are the experiment control. Relative transduction 
activity of the P21mR8R (E) samples contain P21mR8R (F) samples contain 
P21mR8R and L-Histidine. Protein transduction activity was compared to the 
experiment control. Error bars indicate SD (n = 3). * is p<0.05. 
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Figure S5. GET-peptide stability at various pH values mimicking the PLGA 
microenvironment. P21mR8R stability in cell culture media of various pH values (3, 
5 & 7), with and without L-Histidine. pH was adjusted using 1M phosphoric acid 
solution. (A) Schematic of the protein storage and sampling, 200µg/ml P21mR8R 
with or without 200µg/ml L-Histidine solution was prepared with various pH values (3, 
5 &7) and stored at 37ºC. A sample was taken from each solution, at defined time 
points, and diluted 1:10 in fresh cell culture media. Protein was then transduced into 
cells by addition to plated NIH3t3 cells. (B) Fluorescence microscopy images of the 
NIH3t3 cells treated with the samples contain P21mR8R (Scale bar 10μm). (C) 
Fluorescence microscopy images of the NIH3t3 cells treated with the samples 
contain P21mR8R and L-Histidine (Scale bar 10μm). Flow cytometry histograms 
showing cellular uptake of P21mR8R after application of the samples to NIH3t3 cells 
(D) samples contain P21mR8R (E) samples contain P21mR8R and L-Histidine. The 
red histograms represent P21mR8R samples taken at day 1, while the grey 
histograms represent day 7 samples, black histograms are the experiment control. 
Relative biological activity of the P21mR8R (F) samples contain P21mR8R (G) 
samples contain P21mR8R and L-Histidine. Protein transduction activity was 
compared to the experiment control. Error bars indicate SD (n = 3). * is p<0.05, ** is 
p<0.01. 
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Figure S6. GET-peptide stability at various pH values mimicking the PLGA 
microenvironment. P21mR8R stability in cell culture media of various pH values (3, 
5 & 7), with and without L-Histidine. pH was adjusted using 1M hydrochloric acid 
solution. A sample was taken from each solution, at defined time points, and diluted 
1:10 in fresh cell culture media. Protein was then transduced into cells by addition to 
plated NIH3t3 cells. (A) Fluorescence microscopy images of the NIH3t3 cells treated 
with the samples contain P21mR8R (Scale bar 10μm). (B) Fluorescence microscopy 
images of the NIH3t3 cells treated with the samples contain P21mR8R and L-
Histidine (Scale bar 10μm). Flow cytometry histograms showing cellular uptake of 
P21mR8R after application of the samples to NIH3t3 cells. (C) Samples contain 
P21mR8R (D) samples contain P21mR8R and L-Histidine. The red histograms 
represent P21mR8R samples taken at day 1, while the grey histograms represent 
day 7 samples, black histograms are the experiment control. Relative transduction 
activity of the P21mR8R (E) samples contain P21mR8R (F) samples contain 
P21mR8R and L-Histidine. Protein transduction activity was compared to the 
experiment control. Error bars indicate SD (n = 3). * is p<0.05, ** is p<0.01. 
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Figure S7. GET-peptide stability at various pH values mimicking the PLGA 
microenvironment. P21mR8R stability in cell culture media of various pH values (3, 
5 & 7), with and without L-Histidine. pH was adjusted using 1M sulfuric acid solution. 
A sample was taken from each solution, at defined time points, and diluted 1:10 in 
fresh cell culture media. Protein was then transduced into cells by addition to plated 
NIH3t3 cells. (A) Fluorescence microscopy images of the NIH3t3 cells treated with 
the samples contain P21mR8R (Scale bar 10μm). (B) Fluorescence microscopy 
images of the NIH3t3 cells treated with the samples contain P21mR8R and L-
Histidine (Scale bar 10μm). Flow cytometry histograms showing cellular uptake of 
P21mR8R after application of the samples to NIH3t3 cells (C) samples contain 
P21mR8R (D) samples contain P21mR8R and L-Histidine. The red histograms 
represent P21mR8R samples taken at day 1, while the grey histograms represent 
day 7 samples, black histograms are the experiment control. Relative transduction 
activity of the P21mR8R (E) samples contain P21mR8R (F) samples contain 
P21mR8R and L-Histidine. Protein transduction activity was compared to the 
experiment control. Error bars indicate SD (n = 3). * is p<0.05. 
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Figure S8. L-Histidine does not change pH values. pH values for media before 
and after addition of L-Histidine (200µg/ml). pH was initially adjusted using 1M acetic 
acid solution. Error bars indicate SD (n = 3). 
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Figure S9. L-Histidine promotes GET-peptide activity. Effect of L-Histidine on 
P21mR8R stability upon storage in cell culture media of pH 3, adjusted using 1M 
acetic acid solution. 200µg/ml P21mR8R solution of pH 3 was prepared and stored 
at 37ºC for 7 days. A sample was taken from the solution, after 7 days, and diluted 
1:10 in fresh cell culture media, producing a P21mR8R solution of 20µg/ml. 20µg of 
L-Histidine was then added to the solution. Protein was then transduced into cells by 
addition to plated NIH3t3 cells. (A) Fluorescence microscopy images of the NIH3t3 
cells treated with the sampled P21mR8R (Scale bar 10μm). (B) Flow cytometry 
histograms showing cellular uptake of P21mR8R after application of the sample to 
NIH3t3 cells. The red histograms represent P21mR8R sample, black histogram is 
the experiment control. 
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Figure S10. Poly-L-Histidine promotes GET-peptide activity. Effect of Poly-L-
Histidine on P21mR8R stability upon storage in cell culture media of various pH 
values (3, 5 & 7), adjusted using 1M acetic acid solution. (A) Schematic of the 
protein storage and sampling, 200µg/ml P21mR8R and 200µg/ml Poly-L-Histidine 
solution was prepared with various pH values (3, 5 &7) and stored at 37ºC. A sample 
was taken from each solution, at defined time points, and diluted 1:10 in fresh cell 
culture media. Protein was then transduced into cells by addition to plated NIH3t3 
cells. (B) Fluorescence microscopy images of the NIH3t3 cells treated with the 
sampled P21mR8R (Scale bar 10μm). (C) Flow cytometry histograms showing 
cellular uptake of P21mR8R after application of the samples to NIH3t3 cells. The red 
histograms represent P21mR8R samples taken at day 1, while the grey histograms 
represent day 7 samples, black histograms are the experiment control. (D) Relative 
transduction activity of the sampled P21mR8R. Protein transduction activity was 
compared to the experiment control. Error bars indicate SD (n = 3). 
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Figure S11. Estimation of P21mR8R molecular weight using SDS-PAGE. 
P21mR8R was incubated for 7 days in media of various pH conditions (3 & 7) with 
and without L-histidine. P21mR8R band was then compared to fresh protein sample. 
DMEM media containing FCS was used as a control. 
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Table S1. Blank MPs surface charge at various pH conditions (3, 5 & 7) 
 
 
 
 
Table S2. P21mR8R, mR, P21 & 8R theoretical molecular weights, isoelectric points 
and charge at various pH values. 
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Graphical Abstract 
